Back to overview

Suicidality test being brought to market

U.S. company Sundance Diagnostics has licensed genetic markers that predict suicide risk when antidepressant drugs are prescribed

The new test, based on research carried out at the Max Planck Institute of Psychiatry, should help doctors to decrease the risk of suicidality in patients treated with antidepressants who show certain gene markers. Sundance plans to launch the test immediately as a laboratory developed test. In addition, clinical studies in support of a U.S. Food and Drug Administration submission for market clearance, CE marking and reimbursement will be initiated. Sundance expects to submit its application to the agencies within 18 months.

DNA microarrays are used for diagnostics and to study the expression of genes. A further application is that of genome analysis.
© MPI of Psychiatry

Researchers at the Max Planck Institute of Psychiatry discovered when suicidality occurred it happened within two weeks of beginning treatment, or increasing dosage, for 59% of patients. Altogether, 8.1% of patients studied suffered from this adverse side effect of antidepressant medications. Since 2005, in the United States, Canada and some European countries, antidepressants have carried a warning alerting the doctor and the patient to the serious risk of medication-induced suicidality. Up until now, however, doctors have had no indications as to which patients may be at risk. Sundance CEO Kim Bechthold stated, “Our hope is that the new test will assist the physician in significantly reducing the risk of suicide emerging from antidepressant drug use and will provide patients and families with valuable personal information to use with their doctors in weighing the risks and benefits of the medications.”

Scientists at the Max Planck Institute of Psychiatry in Munich have now discovered 79 genetic biomarkers that had a 91% probability of correctly classifying patients at risk of antidepressant-induced suicide.

The researchers also discovered that the increased risk for suicide is not limited to individuals under the age of 25, as described in the warning by the American regulatory agency FDA. Instead, the risk was found in the studies to be present across all ages from 18 to 75. In the United States, more than 9 million new antidepressant drugs are prescribed annually (IMS 2006 National Prescription Drug Audit).

The licensing agreement with Sundance Diagnostics was concluded with Max-Planck-Innovation, the Max Planck Society's technology transfer organization.

Original publication
Andreas Menke, Katharina Domschke, Darina Czamara, Torsten Klengel, Johannes Hennings, Susanne Lucae, Bernhard T Baune, Volker Arolt, Bertram Müller-Myhsok, Florian Holsboer and Elisabeth B Binder.

Genome-Wide Association Study of Antidepressant Treatment-Emergent suicidal Ideation

Neuropsychopharmacology (2012) 37, 797-807; doi:10.1038/npp.2011.257; published online 11 January 2012


Contact
Max Planck Institute of Psychiatry
MD PhD Elisabeth Binder
Director
Phone +49 89 30622-301
Email binder@mpipsykl.mpg.de

Dr. Andreas Menke
Scientist
Phone +49 8930622-1
Email menke@mpipsykl.mpg.de

Press contact
Kim Bechthold
Sundance Diagnostics
Phone +1 303 862 2770,
Email kbech@sundancedx.com

News alert

Do you want to receive our newsletter and press releases?
Subscribe here

Media contact

Markus Berninger
Phone: (089) 290919-30